Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 28, 2015 11:26 PM ET

Pharmaceuticals

Company Overview of Promentis Pharmaceuticals, Inc.

Company Overview

Promentis Pharmaceuticals Inc. discover, develop and market new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. Promentis Pharmaceuticals Inc. was founded in 2006 and is based in Milwaukee, Wisconsin.

826 North Plankinton Avenue

Suite 300

Milwaukee, WI 53203

United States

Founded in 2006

Phone:

262-302-9039

Key Executives for Promentis Pharmaceuticals, Inc.

Chief Executive Officer and President
Director
Compensation as of Fiscal Year 2014.

Promentis Pharmaceuticals, Inc. Key Developments

Promentis Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 04:45 PM

Promentis Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 04:45 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Promentis Pharmaceuticals, Inc. Appoints Chad Beyer as President and Chief Executive Officer

Promentis Pharmaceuticals, Inc. announced that Chad Beyer, Ph.D., MBA, has been appointed as President and Chief Executive Officer. With nearly 20 years experience, Dr. Beyer's career encompasses research, discovery and the business development of medications intended for central nervous system (CNS) and neurological disorders. As an entrepreneur, Dr. Beyer has founded a biotech consulting company and helped launch a specialty pharmaceutical company focused on developing treatments for acute pain conditions. For more than a decade, Dr. Beyer worked in the Discovery Neuroscience group at Wyeth Pharmaceuticals, where he held multiple positions of increasing responsibility, including Head of Neurochemistry. During his time at Wyeth, he also led several drug discovery teams and managed a group of scientists that contributed to the submission of more than 30 INDs and generated supporting data for the commercialization and life-cycle management of Effexor(R) and Pristiq(R), two of the company's blockbuster medications. He is an editor of Next Generation Antidepressants and is co-founder of the journal Technology Transfer & Entrepreneurship. Dr. Beyer also serves as an adjunct faculty member at Thomas Jefferson University where he teaches Bioventure Management.

Similar Private Companies By Industry

Company Name Region
Abbott Chemicals, Inc. United States
Ceva Biomune United States
RelaxZen, Inc. United States
FidoPharm, Inc. United States
Orahealth Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Promentis Pharmaceuticals, Inc., please visit www.promentispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.